GlobeNewswire Inc.T3·4mo ago
TCRX TScan Therapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TCRX
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 142
- List Date
- 2021-07-16
- CIK
- 0001783328
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($0.18) (3 est.)
- Headquarters
- Waltham, MA
- Homepage
- https://www.tscan.com
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | 2.11% | 6.43% | -10.51% | -16.69% | 0.00% | -3.73% |
| Feb | -- | -10.26% | 62.98% | 31.07% | -13.58% | 3.92% | 14.83% |
| Mar | -- | -33.65% | -33.33% | 10.28% | -25.20% | -3.81% | -17.14% |
| Apr | -- | -25.61% | 1.34% | -3.62% | 26.38% | 12.62% | 2.22% |
| May | -- | 50.94% | 40.24% | -0.81% | -7.74% | -11.48% | 14.23% |
| Jun | -- | -0.79% | 8.23% | -31.01% | -0.68% | -2.96% | -5.44% |
| Jul | -7.62% | 37.19% | -5.88% | 20.40% | 21.68% | -29.91% | 5.98% |
| Aug | -11.10% | -27.63% | 8.68% | -17.57% | 11.11% | 0.87% | -5.94% |
| Sep | -5.66% | 8.54% | 4.07% | -7.61% | 4.00% | -52.80% | -8.24% |
| Oct | 1.51% | -9.70% | 41.03% | -8.84% | -7.18% | -40.25%* | -3.90% |
| Nov | -7.93% | -21.60% | 80.39% | -3.64% | -10.48% | -- | 7.35% |
| Dec | -35.90% | -28.24% | -10.03% | -37.32% | -1.96% | -- | -22.69% |
| Total | -53.58% | -62.92% | 333.42% | -56.93% | -28.56% | -80.72% | 8.45% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.25
SMA 50: $0.41
SMA 200: $0.87
Current: $0.19
EMA 12: $0.23
EMA 26: $0.28
MACD: -0.0545 | Signal: 0.0068
BEARISH
ADX (14): 55.32
STRONG TREND
+DI: 7.37
−DI: 36.31
Momentum Oscillators
RSI (14): 25.83
OVERSOLD
Stoch %K: 7.61
Stoch %D: 11.16
Williams %R: -90.58
Volume & Volatility
BB Upper: $0.33
BB Lower: $0.17
NEUTRAL
OBV: -26,064,964
Vol SMA 20: 616,371
Vol ROC: 65.72%
ATR: $0.03
True Range: $0.02
HV 20: 108.4%
HV 30: 100.9%
HV 60: 140.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: TCRX
Executive Summary
Confidence Level: 7/10 (BULLISH)
Key Drivers and Primary Risks: Positive news sentiment, strong technical momentum, and low volatility are the key drivers. High beta and high volatility are the primary risks.
Investment Thesis: TCRX is a biotech stock with significant potential for growth, driven by its pipeline of promising treatments for hematology disorders. The recent positive news headlines and strong technical momentum suggest that the stock has further upside potential.
Recent News Sentiment Impact: The positive news sentiment from the last 10 articles has contributed to the bullish tone in the market and the stock's price increase.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Bullish
Support/Resistance Levels:
- Resistance: $1.18
- Support: $0.98 and $0.77
Momentum Signals:
- RSI interpretation: Neutral (54.82)
- MACD signal: Bullish momentum (0.03 / Signal: 0.03 / Histogram: 0.00)
- Bollinger Bands position: Neutral
Volume Analysis: Volume trends and institutional interest signals suggest a high level of interest in the stock, indicating potential for further price increases.
News & Sentiment Analysis
Recent Headlines Summary: All recent headlines are positive, highlighting the company's progress in its pipeline development and regulatory approvals.
Sentiment Assessment: The overall sentiment is POSITIVE (100%).
Catalyst Identification: FDA clearance of investigational new drug applications for Heme candidates TSC-102-A01 and TSC-102-A03 could be a catalyst for further price increases.
Market Narrative: The news aligns with the technical signals, suggesting that the stock has further upside potential.
Risk & Volatility Assessment
Beta Interpretation: High risk (1.86) relative to the market (SPY).
Volatility Regime: High volatility regime (0.87), indicating a high level of price movement.
Options Market Signals: No options data available, but implied volatility is likely to be influenced by the stock's high volatility.
Downside Protection: Support levels at $0.98 and $0.77 should provide some downside protection.
Market Context & Positioning
Sector Performance: The biotech sector has been performing well, with TCRX outperforming its peers.
Institutional Activity: High institutional interest suggests that professionals are buying into the stock's potential.
Correlation Analysis: Correlation with the market (R-squared) is 0.27, indicating a relatively independent movement.
Relative Valuation: The stock is trading within its trading range, suggesting that it may have further upside potential.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $1.18
- Support: $0.98 and $0.77
Breakout/Breakdown Levels: A breakout above $1.18 could trigger a significant move higher, while a breakdown below $0.98 could indicate a trend reversal.
Time-Sensitive Catalysts: FDA clearance of investigational new drug applications for Heme candidates TSC-102-A01 and TSC-102-A03 could be a catalyst for further price increases.
Risk Management: Stop-loss levels should be set at $1.05, with position sizing considerations based on the stock's high volatility.
Note: The analysis is based on the provided data and may not reflect actual market performance or future events.
Generated
News
All TCRX news →
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·10mo ago
BenzingaT3·10mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·17mo ago
BenzingaT3·17mo ago
Showing 1–10 of 50
Page 1 of 5
TCRX Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.6268
Alpha: -216.22%
Correlation: 0.2086
R-Squared: 4.4%
Stock Volatility: 99.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own TCRX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $1.3M | #2190 of 3138 | -2.8% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.1M | #2847 of 3716 | -20.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $989K | #3710 of 6285 | +216.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TCRX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
TCRX Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Gavin MacBeath | Chief Executive Officer | Award (A) | +1,000,000 | — | EDGAR | |
| 2026-10-02 | Zoran Zdraveski | See Remarks | Award (A) | +300,000 | — | EDGAR | |
| 2026-05-22 | Katina Dorton | Director | Grant (A) | +67,000 opt | — | EDGAR | |
| 2026-05-22 | Garry A Nicholson | Director | Grant (A) | +67,000 opt | — | EDGAR | |
| 2026-05-22 | Gabriela Gruia | Director | Grant (A) | +67,000 opt | — | EDGAR | |
| 2026-05-22 | Barbara Klencke | Director | Grant (A) | +67,000 opt | — | EDGAR | |
| 2026-05-22 | Keith Woods | Director | Grant (A) | +67,000 opt | — | EDGAR | |
| 2026-05-22 | 667, L.P. | Director | Grant (A) | +804,000 opt | — | EDGAR | |
| 2026-01-22 | Gavin MacBeath | Chief Executive Officer | Grant (A) | +1,165,000 opt | — | EDGAR | |
| 2026-01-22 | Chrystal Louis | Chief Medical Officer | Grant (A) | +420,000 opt | — | EDGAR | |
| 2026-01-22 | Jason Amello | Chief Financial Officer | Grant (A) | +350,000 opt | — | EDGAR | |
| 2026-01-22 | Zoran Zdraveski | See Remarks | Grant (A) | +350,000 opt | — | EDGAR | |
| 2026-01-22 | Leiden Dworak | See Remarks | Grant (A) | +100,000 opt | — | EDGAR | |
| 2025-12-23 | Weston Nichols | 10%+ Owner | Buy (P) | +323,602 | $0.90 | $291.1K | EDGAR |
| 2025-07-02 | Gabriela Gruia | Director | Grant (A) | +67,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TCRX Insider Holdings
5 insiders · @ $0.19
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Weston Nichols | 10%+ Owner | 8,019,148 | $1.52M | $163.1K | 2 | 2025-12-23 |
| 2 | Lynx1 Capital Management LP | 10%+ Owner | 6,746,141 | $1.28M | $6.99M | 5 | 2025-05-21 |
| 3 | Gavin MacBeath | Chief Executive Officer | 1,049,767 | $199.1K | $31.1K | 8 | 2026-10-02 |
| 4 | Zoran Zdraveski | See Remarks | 304,716 | $57.8K | -$916.9K | 10 | 2026-10-02 |
| 5 | Barbara Klencke | Director | 70,000 | $13.3K | $108.0K | 8 | 2026-05-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TCRX Board & Officers
As of SEC filings through Oct 2, 2026Directors 13
- 667, L.p. (entity) · since Jul 15, 2021
- Baker Bros. Advisors (GP) LLC (entity) · since Jul 15, 2021
- Baker Bros. Advisors LP (entity) · since Jul 15, 2021
- Baker Brothers Life Sciences LP (entity) · since Jul 15, 2021
- Felix Baker · since Jul 15, 2021
- Gabriela Gruia · since Jul 15, 2021
- Julian Baker · since Jul 15, 2021
- Katina Dorton · since Jul 15, 2021
- Stephen R Biggar · since Jul 15, 2021
- Barbara Klencke · since Apr 6, 2023
- Gavin MacBeath · listed since Jun 2023
- Keith Woods · since Dec 6, 2023
- Garry A Nicholson · since Jun 12, 2024
Officers 4
- Gavin MacBeath · Chief Executive Officer · listed since Jun 2023
- Jason Amello · Chief Financial Officer · since Jan 29, 2024
- Chrystal Louis · Chief Medical Officer · since Apr 22, 2024
- Zoran Zdraveski · Chief Legal and Strategy Officer · listed since Aug 2024
10% owners 2
- Lynx1 Capital Management LP (entity) · since May 31, 2023
- Weston Nichols · since May 31, 2023
Changes in the last 10 years (52)
| Mar 31, 2026 | The company announced the departure of Leiden Dworak as Principal Accounting Officer in an SEC filing |
| Aug 22, 2025 | Leiden Dworak first listed as Principal Accounting Officer in an SEC filing |
| Feb 11, 2025 | Leiden Dworak reported in an SEC filing no longer being Chief Accounting Officer |
| Aug 27, 2024 | Zoran Zdraveski listed as Chief Legal and Strategy Officer (previously Chief Legal Officer) in SEC filings |
| Jun 12, 2024 | The company announced the departure of Timothy J Barberich from the board in an SEC filing |
| Jun 12, 2024 | Garry A Nicholson became a director |
| Apr 22, 2024 | Chrystal Louis became Chief Medical Officer |
| Jan 29, 2024 | Jason Amello became Chief Financial Officer |
| Dec 6, 2023 | Keith Woods became a director |
| Jul 21, 2023 | Leiden Dworak became Chief Accounting Officer |
| Jun 27, 2023 | The company announced the departure of Brian M. Silver as Chief Financial Officer in an SEC filing |
| Jun 15, 2023 | Gavin MacBeath listed as Chief Executive Officer (previously Chief Scientific and Operations Officer) in SEC filings |
| Jun 15, 2023 | Gavin MacBeath first listed as a director in an SEC filing |
| Jun 2, 2023 | Julian Baker no longer listed as a 10% owner in SEC filings |
| Jun 2, 2023 | Felix Baker no longer listed as a 10% owner in SEC filings |
| Jun 2, 2023 | Baker Brothers Life Sciences LP no longer listed as a 10% owner in SEC filings |
| Jun 2, 2023 | Baker Bros. Advisors LP no longer listed as a 10% owner in SEC filings |
| Jun 2, 2023 | Baker Bros. Advisors (GP) LLC no longer listed as a 10% owner in SEC filings |
| Jun 2, 2023 | 667, L.p. no longer listed as a 10% owner in SEC filings |
| May 31, 2023 | Weston Nichols became a 10% owner |
| May 31, 2023 | Lynx1 Capital Management LP became a 10% owner |
| May 26, 2023 | EcoR1 Capital, LLC became a 10% owner |
| Apr 6, 2023 | Barbara Klencke became a director |
| Mar 27, 2023 | The company announced the departure of David P Southwell from the board in an SEC filing |
| Mar 27, 2023 | The company announced the departure of David P Southwell as Chief Executive Officer in an SEC filing |
| Jul 27, 2022 | Gavin MacBeath listed as Chief Scientific and Operations Officer (previously Chief Scientific Officer) in SEC filings |
| Jul 5, 2022 | Debora Barton became Chief Medical Officer |
| Sep 7, 2021 | Zoran Zdraveski became Chief Legal Officer |
| Jul 15, 2021 | William Desmarais became Chief Business Officer |
| Jul 15, 2021 | Timothy J Barberich became a director |
| Jul 15, 2021 | Stephen R Biggar became a director |
| Jul 15, 2021 | Katina Dorton became a director |
| Jul 15, 2021 | Julian Baker became a director |
| Jul 15, 2021 | Julian Baker became a 10% owner |
| Jul 15, 2021 | Ittai Harel became a director |
| Jul 15, 2021 | Gavin MacBeath became Chief Scientific Officer |
| Jul 15, 2021 | Gabriela Gruia became a director |
| Jul 15, 2021 | Felix Baker became a director |
| Jul 15, 2021 | Felix Baker became a 10% owner |
| Jul 15, 2021 | David P Southwell became a director |
| Jul 15, 2021 | David P Southwell became Chief Executive Officer |
| Jul 15, 2021 | Christoph H Westphal became a director |
| Jul 15, 2021 | Christoph H Westphal became a 10% owner |
| Jul 15, 2021 | Brian M. Silver became Chief Financial Officer |
| Jul 15, 2021 | Baker Brothers Life Sciences LP became a director |
| Jul 15, 2021 | Baker Brothers Life Sciences LP became a 10% owner |
| Jul 15, 2021 | Baker Bros. Advisors LP became a director |
| Jul 15, 2021 | Baker Bros. Advisors LP became a 10% owner |
| Jul 15, 2021 | Baker Bros. Advisors (GP) LLC became a director |
| Jul 15, 2021 | Baker Bros. Advisors (GP) LLC became a 10% owner |
| Jul 15, 2021 | 667, L.p. became a director |
| Jul 15, 2021 | 667, L.p. became a 10% owner |
Not reported recently (5)
- Debora Barton · Last reported as Chief Medical Officer in an SEC filing dated Jun 15, 2023
- EcoR1 Capital, LLC · Last reported as a 10% owner in an SEC filing dated Jun 5, 2023
- William Desmarais · Last reported as Chief Business Officer in an SEC filing dated Jul 27, 2022
- Ittai Harel · Last reported as a director in an SEC filing dated Jun 3, 2022
- Christoph H Westphal · Last reported as a 10% owner in an SEC filing dated Jul 22, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TCRX Proposed Insider Sales (Form 144)
Latest: 2024-08-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-08-23 | ZDRAVESKI ZORAN | Officer | 164,686 | $905.8K | 2024-08-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-05-15 | SOUTHWELL DAVID P | Director | 85,911 | $346.2K | 2023-05-15 | Charles Schwab Company | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold TCRX
3 shown · $820.18K total exposure · 0.00% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.